See also our related blog for the Pediatric Preclinical Testing Initiative.

Monday, April 2, 2012

COG and AACR

The Children's Oncology Group meeting was March 27 - 30 in Minneapolis.  Presentations were given by Jinu on new targeted therapies for undifferentiated sarcomas, and an update of the DIPG preclinical consortium was given by Charles.  
  
The AACR meeting is now in progress, and beginning yesterday with the session on Modeling Pediatric Malignancy where Charles presented, "integrative biology of rhabdomysarcoma
using genetic murine models" and attended the Pediatric Preclinical Testing Program working meeting.  The Pediatric Cancer Town Hall meeting is tonight.  
  
A key new presentation from the Raabe lab is tomorrow, "High-level activation of the Notch pathway in diffuse intrinsic pontine glioma" by Hutt et al (A Johns Hopkins - NCI consortium).  Also presented by Dr. Ian Pollack are the promising early results of a DIPG vaccine trial (caveats not withstanding).  

Wednesday, March 14, 2012

(guest entry) Our Hope: “No Curative Measures” Ends Here

by Nettie Boivin
The Team Julian Foundation
   
I had never in my life heard the term “glioma” until this monster swept into our lives and threatened the life of our son. Julian was a healthy, handsome and fun-loving 4-year-old with huge eyes and an even bigger imagination. It was Nov. 29, 2010, that our beautiful boy was, seemingly overnight and out of nowhere, diagnosed with an inoperable brain stem glioma. Gripped by fear but determined to beat the odds, we researched the best doctors in the country and brought him under the care of top pediatric oncologists at St. Jude Children’s Research Hospital in Memphis.
   
Our diagnosis happened to be the deadliest of all brain tumors with “no known cause or cure.” It was unimaginable and impossible to process that we’d most likely lose our first-born within 18 months. Throughout Julian’s treatment, doctors used terms like “palliative measures” and “grim prognosis.” With every blow, we kept waiting for that next line - some promising shred of a breakthrough that may halt the heartbreak to come.  But much to our dismay, we discovered that little research was currently underway for pediatric gliomas and cures were still years away.
   
In only 7 intense months, filled with beautiful and bittersweet moments,  the incurable disease proved too much. We lost our sweet boy, Julian Bradley Boivin, on July 3, 2011, just three weeks after his 5th birthday.
   
Last March while at St. Jude, Julian met a little girl who also had a DIPG, and together they forged a friendship as two 4-year-olds discussing bravery techniques before daily radiation treatments. This girl's mother and I desperately hoped and prayed these two would be exceptions to this dreaded diagnosis. Now, only months after having to say goodbye to both children, we are committed to making sure our two angels help turn the tide on this incurable disease.
   
An autopsy to resect and study Julian’s tumor wasn't possible when he died over the 4th of July holiday weekend. However the little girl's doctors were able to remove her entire tumor after she passed on in late 2011. Through The Team Julian Foundation’s support of CureSearch for Children’s Cancer, we were told about an important opportunity to partner with Dr. Keller’s Lab and the DIPG Consortium to find chemo agents that would finally combat this sly disease. So, between funding through Julian's foundation and the donation of this little girl's tumor sample, we believe this is Julian’s and the little girl's way of having a big impact on a world they were a part of for such a short but wonderful time.
   
By supporting the DIPG Consortium, we hope to see a day very soon when other children and their families facing this disease won’t ever have to hear the words “no curative measures” again.

Sunday, February 19, 2012

VIP Visitor !

We had a VIP visitor on Friday, Josh.  Josh's life has by chance been touched by Ewing's sarcoma and he is now a survivor.  Josh told his story in his own words for our StoryCorp project with the Northwest Sarcoma Foundation:  to hear his interview, or his mother April's perspective via her interview, click here.  
   


We appreciate patients stopping by the lab, and the accountability that this brings.  Josh's Dad gives the universal perspective, "Every parent around the world wants one simple thing…to see their kids grow up."  It's our intention to find those new treatments that Give Back Childhood.
  
[ update 07/03/2012:  See Josh's martial arts talent and broader story here. ] 
  
[ For the StoryCorps interviews with Josh and his mom, go here. ]

Wednesday, February 8, 2012

Scientific Writer needed

We are looking for a volunteer technical writer from the community to co-author a scientific paper on childhood cancer research from results already compiled.  This endeavor is an experiments of sorts to see whether we can begin to blend the community with academics to create a seamless and efficient way of moving towards new treatments for childhood cancers.  If you have time and interest, please contact Charles at keller (at) ohsu.edu.   with thanks, the Keller Lab team.  

Sunday, January 29, 2012

Our thanks to the Ethan Jostad Foundation

We are grateful to partner with the Ethan Jostad Foundation for Childhood Cancer in the search for treatments of alveolar rhabdomyosarcoma.  This foundation has both patient/family assistance and research as the center of their mission.  We are thankful for the gift of $11,400 that supports the preclinical studies of a specific new agent potentially capable of stopping tumor cell spreading (metastasis).  These studies will specifically employ our genetically-engineered mouse model of alveolar rhabdomyosarcoma.  We are honored to be part of Ethan's rememberance.     
  
[ pictured:  Guangheng Li and Charles Keller (left) with Chris and Kim Jostad (right) ]  

Tuesday, January 24, 2012

Graphics Volunteer Needed

We are hoping to work with a volunteer in the community with graphic arts/communication experience.  The project is about 6 weeks long and may take 8-12 hours a week.  If you have time and interest, please contact Charles at keller (at) ohsu.edu.   with thanks, the Keller Lab team

Tuesday, January 17, 2012

Congratulations, Ken and Anu!

Congratulations to authors Ken and Anu whose manuscript describing the role of Protein Kinase C iota in rhabdomyosarcoma was accepted today to the journal, Oncogene.  Co-authors include lab alumni Laura and Sheila, UTHSCSA biostatistics collaborators Joel Michalek and Lee Ann Zarzabal, Mayo PKC biology collaborators Capella Weems and Alan Fields, and long-time sarcoma pathologist collaborator Brian Rubin at Cleveland Clinic.  This work was supported by by NIH/NCI grant 1R01CA133229-04 and -05 awarded to the Keller lab and NIH/NCI grant 4R01CA081436-13 and the V Foundation for Cancer Research awarded to Dr. Fields.  
  
For a full list of KellerLab & collaborator publications in the last year and beyond, see http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/10calZ-r8sAIil6mkZzynGqAV/?sort=date&direction=descending .
   
[ 2/22/2012:  Ken's article, Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma, is now online here.